Extended High Dose Letrozole Regimen Versus Short Low Dose Letrozole Regimen as an Adjuvant to GnRH Antagonist Protocol in the Management of Poor Responders Undergoing IVF-ET

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this randomized controlled trial is to compare the efficacy of extended high dose letrozole regimen (5 mg /day for the first 5 days of cycle and 2.5 mg/day for the subsequent 3 days ) with short low dose letrozole regimen (2,5 mg/day from cycle day 3 to 7 ) as an adjuvant to GnRH antagonist protocol in the management of patients with poor ovarian response undergoing IVF-ET.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cairo University
• Collaborator: Ahmed Elgazzar Hospital
• Treatments: Letrozole; LHRH, N-acetyl-(4-chlorophenylalanyl)(1)-(4-chlorophenylalanyl)(2)-tryptophyl(3)-arginyl(6)-alanine(10)-; Prolactin Release-Inhibiting Factors

Criteria

Inclusion Criteria:

• Patients who produced less than three mature follicles in response to standard GnRH agonist long protocol in their first IVF cycle

Exclusion Criteria:

• Age > 42 years

• FSH> 12 IU/L

• Irregular menstrual cycles

• Unilateral ovary

• Polycystic ovary syndrome

• Endometriosis

• Male factor of infertility requiring ICSI

• History of recurrent miscarriage

• Endocrinologic disorders

• Systemic disease contraindicating pregnancy